Chemical Compound Review:
Cordanum 1-cyclohexyl-3-[4-[2-hydroxy- 3-(tert...
Synonyms:
Talinolol, Talinololum, SureCN78047, CHEMBL152067, AG-K-15103, ...
Weitschies,
Bernsdorf,
Giessmann,
Zschiesche,
Modess,
Hartmann,
Mrazek,
Wegner,
Nagel,
Siegmund,
Siegmund,
Ludwig,
Giessmann,
Dazert,
Schroeder,
Sperker,
Warzok,
Kroemer,
Cascorbi,
Chiou,
Chung,
Wu,
Schwarz,
Gramatté,
Krappweis,
Berndt,
Oertel,
von Richter,
Kirch,
Gramatté,
Oertel,
Schwarz,
Seemann,
Oertel,
Miehlke,
Kuhlisch,
Fromm,
Kim,
Bailey,
Kirch,
- Anti-anginal and anti-ischemic effects of the selective beta-blocker talinolol in patients with stable angina pectoris. Faulhaber, H.D., Weigmann, I., Lang, U., Weinsberg, F., Terhaag, B. International journal of clinical pharmacology and therapeutics. (2005)
- The actions of talinolol, a beta 1-selective beta blocker, in cardiac arrhythmia and acute myocardial infarction. Assmann, I. Current medical research and opinion. (1995)
- Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers. Krueger, M., Achenbach, H., Terhaag, B., Haase, H., Richter, K., Oertel, R., Preiss, R. International journal of clinical pharmacology and therapeutics. (2001)
- Effects of some beta-adrenoceptor blockers on avoidance learning in rats. Staneva-Stoytcheva, D., Astrug, A., Ivanov, D. Methods and findings in experimental and clinical pharmacology. (1989)
- P-glycoprotein and surfactants: effect on intestinal talinolol absorption. Bogman, K., Zysset, Y., Degen, L., Hopfgartner, G., Gutmann, H., Alsenz, J., Drewe, J. Clin. Pharmacol. Ther. (2005)
- Grapefruit juice ingestion significantly reduces talinolol bioavailability. Schwarz, U.I., Seemann, D., Oertel, R., Miehlke, S., Kuhlisch, E., Fromm, M.F., Kim, R.B., Bailey, D.G., Kirch, W. Clin. Pharmacol. Ther. (2005)
- Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans. Schwarz, U.I., Gramatté, T., Krappweis, J., Berndt, A., Oertel, R., von Richter, O., Kirch, W. Clin. Pharmacol. Ther. (1999)
- The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Siegmund, W., Ludwig, K., Giessmann, T., Dazert, P., Schroeder, E., Sperker, B., Warzok, R., Kroemer, H.K., Cascorbi, I. Clin. Pharmacol. Ther. (2002)
- Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans. Gramatté, T., Oertel, R., Terhaag, B., Kirch, W. Clin. Pharmacol. Ther. (1996)
- Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Gramatté, T., Oertel, R. Clin. Pharmacol. Ther. (1999)
- Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Westphal, K., Weinbrenner, A., Zschiesche, M., Franke, G., Knoke, M., Oertel, R., Fritz, P., von Richter, O., Warzok, R., Hachenberg, T., Kauffmann, H.M., Schrenk, D., Terhaag, B., Kroemer, H.K., Siegmund, W. Clin. Pharmacol. Ther. (2000)
- Intestinal drug efflux: formulation and food effects. Wagner, D., Spahn-Langguth, H., Hanafy, A., Koggel, A., Langguth, P. Adv. Drug Deliv. Rev. (2001)
- Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Westphal, K., Weinbrenner, A., Giessmann, T., Stuhr, M., Franke, G., Zschiesche, M., Oertel, R., Terhaag, B., Kroemer, H.K., Siegmund, W. Clin. Pharmacol. Ther. (2000)
- Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. Bernsdorf, A., Giessmann, T., Modess, C., Wegner, D., Igelbrink, S., Hecker, U., Haenisch, S., Cascorbi, I., Terhaag, B., Siegmund, W. British journal of clinical pharmacology. (2006)
- The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. Weitschies, W., Bernsdorf, A., Giessmann, T., Zschiesche, M., Modess, C., Hartmann, V., Mrazek, C., Wegner, D., Nagel, S., Siegmund, W. Pharm. Res. (2005)
- Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Giessmann, T., May, K., Modess, C., Wegner, D., Hecker, U., Zschiesche, M., Dazert, P., Grube, M., Schroeder, E., Warzok, R., Cascorbi, I., Kroemer, H.K., Siegmund, W. Clin. Pharmacol. Ther. (2004)
- Stereoselective disposition of talinolol in man. Zschiesche, M., Lemma, G.L., Klebingat, K.J., Franke, G., Terhaag, B., Hoffmann, A., Gramatté, T., Kroemer, H.K., Siegmund, W. Journal of pharmaceutical sciences. (2002)
- Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. Chiou, W.L., Chung, S.M., Wu, T.C. Pharm. Res. (2000)
- Dose-effect and kinetic-dynamic relationships of the beta-adrenoceptor blocking properties of various doses of talinolol in healthy humans. de Mey, C., Schroeter, V., Butzer, R., Jahn, P., Weisser, K., Wetterich, U., Terhaag, B., Mutschler, E., Spahn-Langguth, H., Palm, D. J. Cardiovasc. Pharmacol. (1995)
- Quantitation of talinolol and other beta-blockers by capillary electrophoresis for in vitro drug absorption studies. Awadallah, B., Schmidt, P.C., Holzgrabe, U., Wahl, M.A. Electrophoresis (2003)
- Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans. Tubic, M., Wagner, D., Spahn-Langguth, H., Weiler, C., Wanitschke, R., B??cher, W.O., Langguth, P. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. (2006)